What's new? Log in Free sign up

Evaxion Biotech A/S (EVAX)

Company Profile

Company profile

Ticker

EVAX

Exchange

Website

www.evaxion-biotech.com

CEO

Mr. Christian Kanstrup M.Sc.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • American National • Gilead Sciences • Biogen • Qiagen • Moderna • Bio-Techne • Acorda Therapeutics • BioNTech SE ...

Former names

Bull Horn Holdings Corp.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

EVAX stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Registration statement (foreign) (amended)

Evaxion pursues agreement with EIB to bolster equity through conversion of debt into equity

Current report (foreign)

Evaxion announces 2025 milestones reflecting continued strong strategy execution

Registration statement (foreign) (amended)

Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress

Registration statement (foreign)

Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing

Current report (foreign)

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

ARMISTICE CAPITAL, LLC

Merck & Co., Inc.

Merck & Co., Inc.

Financial summary

Financial statements Chart EVAX financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q2 2023

EVAX institutional ownership history Ownership history

0.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	8	8	–
Opened positions	2	2	–
Closed positions	2	3	-33.3%
Increased positions	0	3	EXIT
Reduced positions	5	0	NEW

13F shares	Current	Prev Q	Change
Total value	167.15 mm	208.70 mm	-19.9%
Total shares	130.34 k	193.06 k	-32.5%
Total puts	0.00	1.20 k	EXIT
Total calls	12.70 k	18.30 k	-30.6%
Total put/call ratio	–	0.1	–

Largest owners	Shares	Value	Change
Susquehanna International	83.52 k	$108.57 mm	-29.7%
JPM JPMorgan Chase & Co.	29.15 k	$37.90 mm	NEW
Beacon Capital Management	6.88 k	$9.01 mm	0.0%
MS Morgan Stanley	3.45 k	$4.51 mm	-90.5%
Group One Trading	3.16 k	$4.11 mm	-45.6%
Rhumbline Advisers	2.11 k	$2.74 mm	NEW
Simplex Trading	1.85 k	$2.00 k	-78.0%
UBS UBS	222.00	$291.00 k	-96.6%
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Susquehanna International	83.52 k	-35.21 k	-29.7%
MS Morgan Stanley	3.45 k	-32.79 k	-90.5%
JPM JPMorgan Chase & Co.	29.15 k	+29.15 k	NEW
Two Sigma Securities	0.00	-10.44 k	EXIT
Simplex Trading	1.85 k	-6.54 k	-78.0%
UBS UBS	222.00	-6.36 k	-96.6%
Group One Trading	3.16 k	-2.65 k	-45.6%
Rhumbline Advisers	2.11 k	+2.11 k	NEW
Proequities	0.00	0.00
Beacon Capital Management	6.88 k	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Evaxion To Present Preclinical Proof-Of-Concept For Precision ERV Cancer Vaccine Concept At ESMO Immuno-Oncology Congress

Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present preclinical Proof-of-Concept for its precision cancer

Evaxion Receives And Appeals Delisting Determination From Nasdaq, Remains Committed To Nasdaq Listing

Watching Evaxion Biotech; Zacks Small-Cap Research Gives Stock $7.25 Price Valuation

Press releases

From Benzinga Pro

Evaxion announces 2025 milestones reflecting continued strong strategy execution

With most of Evaxion's strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025The 2025 key milestones reflect all parts of Evaxion's strategy for value realizationEvaxion

Evaxion significantly expands vaccine development collaboration with MSD

Agreement provides MSD with options to license Evaxion's preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call and webcast to discuss the agreement on September 27, 2024

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.